Rehnquist revelations
The week's news at a glance.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
You are now subscribed
Your newsletter sign-up was successful
Washington, D.C.
The FBI investigated witnesses who testified against former Chief Justice William Rehnquist during his two confirmation hearings, newly released files reveal. In 1971, when Richard Nixon nominated Rehnquist to the Supreme Court, and again in 1986, when Rehnquist was named chief justice, the FBI gave presidential aides a preview of the testimony of witnesses against him. One concern in 1986 was Rehnquist’s 10-year dependence on the sedative Placydil. Documents reveal that Rehnquist was hospitalized in 1981 to withdraw from the drug, and during his hospitalization doctors reported that he hallucinated, imagined CIA plots against him, and attempted to leave the hospital wearing only pajamas and a bathrobe. Rehnquist died in 2005, and the FBI released its file on him in response to requests under the Freedom of Information Act.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Why is the Trump administration talking about ‘Western civilization’?Talking Points Rubio says Europe, US bonded by religion and ancestry
-
Quentin Deranque: a student’s death energizes the French far rightIN THE SPOTLIGHT Reactions to the violent killing of an ultraconservative activist offer a glimpse at the culture wars roiling France ahead of next year’s elections
-
Secured vs. unsecured loans: how do they differ and which is better?the explainer They are distinguished by the level of risk and the inclusion of collateral